|
1) Wong SC, Chan JK, Lo ES, et al. The contribution of bifunctional SkipDewax pretreatment solution, rabbit monoclonal antibodies, and polymer detection systems in immunohistochemistry. Arch Pathol Lab Med. 2007; 131: 1047-55
|
|
|
|
2) Hatanaka Y, Imaoka Y, Torisu K, et al. A simplified, sensitive immunohistochemical detection system employing signal amplification based on fluorescyl-tyramide/antifluorescein antibody reaction: its application to pathologic testing and research. Appl Immunohistochem Mol Morphol. 2008; 16: 87-93
|
|
|
|
|
|
3) Lau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol. 2002; 10: 97-102
|
|
|
|
|
|
4) Graham AD, Williams AR, Salter DM. TTF-1 expression in primary ovarian epithelial neoplasia. Histopathol. 2006; 48: 764-6
|
|
|
|
|
|
5) Zamecnik J, Chanova M, Kodet R. Expression of thyroid transcription factor 1 in primary brain tumours. J Clin Pathol. 2004; 57: 1111-3
|
|
|
|
|
6) Comperat E, Zhang F, Perrotin C, et al. Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin. Mod Pathol. 2005; 18: 1371-6
|
|
|
|
|
|
7) Lim TK, Teo C, Giron DM, et al. Thyroid transcription factor-1 may be expressed in ductal adenocarcinoma of the prostate: a potential pitfall. J Clin Pathol. 2007; 60: 941-3
|
|
|
|
|
|
8) Hirano T, Gong Y, Yoshida K, et al. Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adeno-carcinoma. Lung Cancer. 2003; 41: 155-62
|
|
|
|
|
|
9) Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med. 2008; 132: 384-96
|
|
|
|
|
|
10) Tsuta K, Ishii G, Nitadori J, et al. Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin. J Pathol. 2006; 209: 78-87
|
|
|
|
|
|
11) Camilo R, Capelozzi VL, Siqueira SA, et al. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol. 2006; 37: 542-6
|
|
|
|
|
|
12) Zhang H, Liu J, Cagle PT, et al. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach. Mod Pathol. 2005; 18: 111-8
|
|
|
|
|
|
13) Au NH, Gown AM, Cheang M, et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol. 2004; 12: 240-7
|
|
|
|
|
|
14) Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol. 2007; 15: 415-20
|
|
|
|
|
|
15) Johansson L. Histopathologic classification of lung cancer: Relevance of cytokeratin and TTF-1 immunophenotyping. Ann Diagn Pathol. 2004; 8: 259-67
|
|
|
|
|
|
16) Rossi G, Marchioni A, Milani M, et al. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol. 2004; 122: 884-93
|
|
|
|
|
|
17) Blaukovitsch M, Halbwedl I, Kothmaier H, et al. Sarcomatoid carcinomas of the lung-are these histogenetically heterogeneous tumors？ Virchows Arch. 2006; 449: 455-61
|
|
|
|
|
|
18) Gonzalez-Aragoneses F, Moreno-Mata N, Cebollero-Presmanes M, et al. Spanish Multicenter Study of Neuroendocrine Tumours of the Lung of the Spanish Society of Pneumo-nology, Thoracic Surgery (EMETNE-SEPAR). Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung. Cancer. 2007; 110: 1776-81
|
|
|
|
|
|
19) Ionescu DN, Treaba D, Gilks CB, et al. Nonsmall cell lung carcinoma with neuroendocrine differentiation─an entity of no clinical or prognostic significance. Am J Surg Pathol. 2007; 31: 26-32
|
|
|
|
|
|
20) Howe MC, Chapman A, Kerr K, et al. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathol. 2005; 46: 195-201
|
|
|
|
|
|
21) Sorhaug S, Steinshamn S, Haaverstad R, et al. Expression of neuroendocrine markers in non-small cell lung cancer. APMIS. 2007; 115: 152-63
|
|
|
|
|
|
22) Hiroshima K, Iyoda A, Shida T, et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. Mod Pathol. 2006; 19: 1358-68
|
|
|
|
|
|
23) Sica G, Vazquez MF, Altorki N, et al. PAX-5 expression in pulmonary neuroendocrine neoplasms: its usefulness in surgical and fine-needle aspiration biopsy specimens. Am J Clin Pathol. 2008; 129: 556-62
|
|
|
|
|
|
24) Torlakovic E, Slipicevic A, Robinson C, et al. Pax-5 expression in nonhematopoietic tissues. Am J Clin Pathol. 2006; 126: 798-804
|
|
|
|
|
|
25) Rugge M, Fassan M, Clemente R, et al. Bronchopulmonary carcinoid: phenotype and long-term outcome in a single-institution series of Italian patients. Clin Cancer Res. 2008; 14: 149-54
|
|
|
|
|
|
26) Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol. 2007; 15: 415-20
|
|
|
|
|
|
27) Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology. 2000; 36: 415-20
|
|
|
|
|
|
28) Nitadori J, Ishii G, Tsuta K, et al. Immuno-histochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel. Am J Clin Pathol. 2006; 125: 682-92
|
|
|
|
|
|
29) Hijiya N, Miyawaki M, Kawahara K, et al. Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma. Hum Pathol. 2008; 39: 316-23
|
|
|
|
|
|
30) Takano T, Ohe Y, Sakamoto H, et al. Genetic, immunohistochemical, and clinical features associated with gefitinib sensitivity in patients with advanced non-small-cell lung cancer (O-190). Lung Cancer. 2005; 49: S63
|
|
|
|
|
|
31) Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2007; 355: 983-91
|
|
|
|
|
|
32) Fujii T, Toyooka S, Ichimura K, et al. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer. 2008; 59: 377-84
|
|
|
|
|